JPWO2021195163A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021195163A5 JPWO2021195163A5 JP2022557121A JP2022557121A JPWO2021195163A5 JP WO2021195163 A5 JPWO2021195163 A5 JP WO2021195163A5 JP 2022557121 A JP2022557121 A JP 2022557121A JP 2022557121 A JP2022557121 A JP 2022557121A JP WO2021195163 A5 JPWO2021195163 A5 JP WO2021195163A5
- Authority
- JP
- Japan
- Prior art keywords
- implant
- sustained release
- biodegradable intraocular
- release biodegradable
- axitinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 claims 51
- 238000013268 sustained release Methods 0.000 claims 27
- 239000012730 sustained-release form Substances 0.000 claims 27
- 239000002202 Polyethylene glycol Substances 0.000 claims 15
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 15
- 229960003005 axitinib Drugs 0.000 claims 15
- 229920001223 polyethylene glycol Polymers 0.000 claims 15
- 239000000017 hydrogel Substances 0.000 claims 14
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000002953 phosphate buffered saline Substances 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000269 nucleophilic effect Effects 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 239000004971 Cross linker Substances 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000005266 casting Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001879 gelation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000012014 optical coherence tomography Methods 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Claims (32)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023186255A JP2024012435A (en) | 2020-03-25 | 2023-10-31 | Ocular implant containing tyrosine kinase inhibitor |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062994391P | 2020-03-25 | 2020-03-25 | |
US62/994,391 | 2020-03-25 | ||
USPCT/US2020/029827 | 2020-04-24 | ||
PCT/US2020/029827 WO2020219890A1 (en) | 2019-04-25 | 2020-04-24 | Ocular hydrogel tyrosine kinase inhibitor implants |
US202063106276P | 2020-10-27 | 2020-10-27 | |
US63/106,276 | 2020-10-27 | ||
US202163148463P | 2021-02-11 | 2021-02-11 | |
US63/148,463 | 2021-02-11 | ||
PCT/US2021/023806 WO2021195163A1 (en) | 2020-03-25 | 2021-03-24 | Ocular implant containing a tyrosine kinase inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023186255A Division JP2024012435A (en) | 2020-03-25 | 2023-10-31 | Ocular implant containing tyrosine kinase inhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2023518820A JP2023518820A (en) | 2023-05-08 |
JPWO2021195163A5 true JPWO2021195163A5 (en) | 2023-08-02 |
JP7378638B2 JP7378638B2 (en) | 2023-11-13 |
Family
ID=77411313
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022557121A Active JP7378638B2 (en) | 2020-03-25 | 2021-03-24 | Intraocular implants containing tyrosine kinase inhibitors |
JP2023186255A Pending JP2024012435A (en) | 2020-03-25 | 2023-10-31 | Ocular implant containing tyrosine kinase inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023186255A Pending JP2024012435A (en) | 2020-03-25 | 2023-10-31 | Ocular implant containing tyrosine kinase inhibitor |
Country Status (20)
Country | Link |
---|---|
US (4) | US11439592B2 (en) |
EP (2) | EP3884929B1 (en) |
JP (2) | JP7378638B2 (en) |
KR (1) | KR20220157462A (en) |
CN (1) | CN115461040A (en) |
AU (2) | AU2021244485B2 (en) |
BR (1) | BR112022018815A2 (en) |
CA (2) | CA3171563A1 (en) |
CL (1) | CL2022002606A1 (en) |
DK (1) | DK3884929T3 (en) |
ES (1) | ES2952677T3 (en) |
FI (1) | FI3884929T3 (en) |
HR (1) | HRP20230800T1 (en) |
HU (1) | HUE062928T2 (en) |
IL (1) | IL296687A (en) |
MX (1) | MX2022010333A (en) |
PL (1) | PL3884929T3 (en) |
PT (1) | PT3884929T (en) |
TW (1) | TW202202138A (en) |
WO (1) | WO2021195163A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113939271A (en) * | 2019-04-25 | 2022-01-14 | 视觉治疗股份有限公司 | Ophthalmic hydrogel tyrosine kinase inhibitor implants |
CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
US20230390189A1 (en) * | 2020-10-27 | 2023-12-07 | Ocular Therapeutix, Inc. | Ocular implant containing an active ingredient |
WO2022204374A1 (en) * | 2021-03-24 | 2022-09-29 | Ocular Therapeutix, Inc. | Implant injector device |
WO2023133278A1 (en) * | 2022-01-09 | 2023-07-13 | Ocular Therapeutix, Inc. | Intracanalicular insert comprising an antimicrobial agent |
WO2023133276A1 (en) * | 2022-01-09 | 2023-07-13 | Ocular Therapeutix, Inc. | Intracanalicular insert comprising a non-steroidal anti-inflammatory agent |
US20230233375A1 (en) * | 2022-01-24 | 2023-07-27 | Celanese Eva Performance Polymers Llc | Implantable Device for Delivery of a Tyrosine Kinase Inhibitor |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993071A (en) | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
US3949750A (en) | 1974-10-07 | 1976-04-13 | Freeman Jerre M | Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same |
US4915684A (en) | 1988-06-21 | 1990-04-10 | Mackeen Donald L | Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus |
US5469867A (en) | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
US6027470A (en) | 1998-06-10 | 2000-02-22 | Eagle Vision, Inc. | Punctum plug and method for inserting the same into the punctual opening |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
US6196993B1 (en) | 1998-04-20 | 2001-03-06 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US7347850B2 (en) | 1998-08-14 | 2008-03-25 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
US6703047B2 (en) | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
US6509327B1 (en) | 1998-09-30 | 2003-01-21 | Alcon Manufacturing, Ltd. | Compositions and methods for treating otic, ophthalmic and nasal infections |
WO2000033764A1 (en) | 1998-12-04 | 2000-06-15 | Pathak Chandrashekhar P | Biocompatible crosslinked polymers |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
ES2292060T3 (en) | 1999-12-17 | 2008-03-01 | Biopolymer Products Of Sweden Ab | MOVING BIOADHESIVE COMPOSITION INCLUDING A POLYPHENOLIC PROTEIN, A POLYMER THAT INCLUDES CARBOHYDRATE GROUPS, FINE PHARMACEUTICAL ACCEPTANCE FILMS AND ITS USES. |
US20040175410A1 (en) | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
US6982090B2 (en) | 2001-05-10 | 2006-01-03 | Gillespie Donald E | More easily visualized punctum plug configurations |
CN1301692C (en) | 2002-09-18 | 2007-02-28 | 阿勒根公司 | Methods and apparatus for delivery of ocular implants |
US20050283109A1 (en) | 2003-03-07 | 2005-12-22 | Peyman Gholam A | Method and apparatus for lacrimal canal obstruction |
US20050197614A1 (en) | 2004-03-04 | 2005-09-08 | Wilson Pritchard | Occlusive biomedical devices, punctum plugs, and methods of use thereof |
US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
WO2005107708A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
WO2006002365A2 (en) | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
BRPI0517924A (en) | 2004-11-02 | 2008-10-21 | Pfizer | polymorphic forms of 6- [2 (methylcarbamoyl) phenylsufanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole |
ATE408432T1 (en) | 2004-11-02 | 2008-10-15 | Sydney Biotech Pty Ltd | EXTRAOCULAR DEVICE |
US8939910B2 (en) | 2006-03-28 | 2015-01-27 | Devicor Medical Products, Inc. | Method for enhancing ultrasound visibility of hyperechoic materials |
US11129690B2 (en) | 2006-03-28 | 2021-09-28 | Devicor Medical Products, Inc. | Method for making hydrogel markers |
US7998497B2 (en) | 2006-03-31 | 2011-08-16 | Qlt Inc. | Nasolacrimal drainage system implants for drug therapy |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US9173773B2 (en) | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
PL2079727T3 (en) | 2006-09-15 | 2016-08-31 | Xcovery Inc | Kinase inhibitor compounds |
US20080114076A1 (en) | 2006-11-09 | 2008-05-15 | Alcon Manufacturing Ltd. | Punctal plug comprising a water-insoluble polymeric matrix |
US8080593B2 (en) | 2006-11-29 | 2011-12-20 | University Of Southern California | Reversible thermoresponsive adhesives for implants |
US8673286B2 (en) | 2007-04-09 | 2014-03-18 | Northwestern University | DOPA-functionalized, branched, poly(aklylene oxide) adhesives |
US20090227981A1 (en) | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
CA2682859C (en) | 2007-04-05 | 2013-10-08 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl)indazole for treatment of abnormal cell growth in mammals |
US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
EP2396070A4 (en) | 2009-02-12 | 2012-09-19 | Incept Llc | Drug delivery through hydrogel plugs |
US20100247606A1 (en) | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
CN102573913B (en) | 2009-07-31 | 2014-06-18 | 阿森迪斯药物股份有限公司 | Biodegradable polyethylene glycol based water-insoluble hydrogels |
KR101756493B1 (en) | 2009-10-29 | 2017-07-10 | 아센디스 파마 에이에스 | Sterilization of biodegradable hydrogels |
US9320647B2 (en) | 2010-03-31 | 2016-04-26 | Ocuject, Llc | Device and method for intraocular drug delivery |
US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
US20130202587A1 (en) | 2011-08-25 | 2013-08-08 | Randox Laboratories Ltd. | Identification of genetic variants |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
CA2858161C (en) | 2011-12-05 | 2020-03-10 | Incept, Llc | Medical organogel processes and compositions |
US10119202B2 (en) | 2012-04-30 | 2018-11-06 | The Johns Hopkins University | Method for preparing electro-mechanically stretched hydrogel micro fibers |
US11779682B2 (en) | 2012-04-30 | 2023-10-10 | The Johns Hopkins University | Electro-mechanically stretched micro fibers and methods of use thereof |
EP2852388A4 (en) | 2012-05-23 | 2016-01-13 | Univ Johns Hopkins | Compounds and methods of use thereof for treating neurodegenerative disorders |
EA034963B1 (en) | 2012-11-08 | 2020-04-13 | Клиасайд Байомедикал, Инк. | Method of treating a posterior segment of the eye disorder |
US10113033B2 (en) | 2013-03-08 | 2018-10-30 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
CA2902372C (en) | 2013-03-08 | 2021-06-15 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
CN105188666A (en) | 2013-04-01 | 2015-12-23 | 阿勒根公司 | Microsphere drug delivery system for sustained intraocular release |
MX2016007345A (en) | 2013-12-06 | 2016-12-09 | Envisia Therapeutics Inc | Intracameral implant for treatment of an ocular condition. |
EP3094284A4 (en) | 2014-01-16 | 2017-12-13 | Ontogenesis, LLC | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
EP3498734B1 (en) | 2014-02-04 | 2021-09-01 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
KR20150115533A (en) * | 2014-04-04 | 2015-10-14 | 씨제이제일제당 (주) | Refining method of organic amine |
EP3229779B1 (en) | 2014-12-10 | 2021-02-03 | Incept, LLC | Hydrogel drug delivery implants |
WO2016178150A1 (en) | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
AU2016261925B2 (en) | 2015-05-12 | 2020-10-01 | Incept, Llc | Drug delivery from hydrogels |
CA2988293A1 (en) | 2015-06-06 | 2016-12-15 | Cloudbreak Therapeutics, Llc | Compositions and methods for treating pterygium |
MX2017016324A (en) | 2015-06-16 | 2018-03-02 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments. |
WO2017015616A1 (en) | 2015-07-22 | 2017-01-26 | Envisia Therapeutics, Inc. | Ocular protein delivery |
AU2016297642A1 (en) | 2015-07-22 | 2018-02-15 | Incept, Llc | Coated punctal plug |
BR112018010671A8 (en) | 2015-11-25 | 2019-02-26 | Incept Llc | shape-changing drug delivery devices and methods |
KR20240052865A (en) | 2016-06-02 | 2024-04-23 | 에이디에스 테라퓨틱스 엘엘씨 | Compositions and methods of using nintedanib for improving glaucoma surgery success |
EP4197527A1 (en) | 2016-09-23 | 2023-06-21 | Incept, LLC | Intracameral drug delivery depots |
CA3035124A1 (en) | 2016-09-29 | 2018-04-05 | Equinox Sciences, Llc. | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
WO2018067882A1 (en) | 2016-10-05 | 2018-04-12 | Titan Pharmaceuticals, Inc. | Implantable devices for drug delivery with reduced burst release |
CN110730655B (en) | 2017-06-13 | 2024-03-05 | 视点制药公司 | Bioerodible drug delivery device |
MX2020009140A (en) | 2018-03-16 | 2020-09-28 | Novartis Ag | Methods for treating ocular diseases. |
CA3132635A1 (en) | 2019-03-05 | 2020-09-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
CN113939271A (en) | 2019-04-25 | 2022-01-14 | 视觉治疗股份有限公司 | Ophthalmic hydrogel tyrosine kinase inhibitor implants |
AU2020283135A1 (en) | 2019-05-31 | 2022-01-06 | Dose Medical Corporation | Bioerodible polyester polymer implants and related methods of use |
CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
US20220080044A1 (en) | 2020-09-14 | 2022-03-17 | National Yang-Ming University | Method for preventing or treating peripheral arterial occlusive disease |
-
2021
- 2021-03-24 CA CA3171563A patent/CA3171563A1/en active Pending
- 2021-03-24 WO PCT/US2021/023806 patent/WO2021195163A1/en active Application Filing
- 2021-03-24 TW TW110110719A patent/TW202202138A/en unknown
- 2021-03-24 PT PT211647375T patent/PT3884929T/en unknown
- 2021-03-24 ES ES21164737T patent/ES2952677T3/en active Active
- 2021-03-24 US US17/210,696 patent/US11439592B2/en active Active
- 2021-03-24 FI FIEP21164737.5T patent/FI3884929T3/en active
- 2021-03-24 HU HUE21164737A patent/HUE062928T2/en unknown
- 2021-03-24 BR BR112022018815A patent/BR112022018815A2/en unknown
- 2021-03-24 PL PL21164737.5T patent/PL3884929T3/en unknown
- 2021-03-24 KR KR1020227036590A patent/KR20220157462A/en not_active Application Discontinuation
- 2021-03-24 AU AU2021244485A patent/AU2021244485B2/en active Active
- 2021-03-24 CA CA3234679A patent/CA3234679A1/en active Pending
- 2021-03-24 MX MX2022010333A patent/MX2022010333A/en unknown
- 2021-03-24 US US17/210,719 patent/US20220079876A1/en not_active Abandoned
- 2021-03-24 JP JP2022557121A patent/JP7378638B2/en active Active
- 2021-03-24 HR HRP20230800TT patent/HRP20230800T1/en unknown
- 2021-03-24 EP EP21164737.5A patent/EP3884929B1/en active Active
- 2021-03-24 EP EP23172378.4A patent/EP4252725A3/en active Pending
- 2021-03-24 DK DK21164737.5T patent/DK3884929T3/en active
- 2021-03-24 CN CN202180030126.1A patent/CN115461040A/en active Pending
- 2021-03-24 IL IL296687A patent/IL296687A/en unknown
-
2022
- 2022-05-13 US US17/744,189 patent/US11534396B2/en active Active
- 2022-09-23 CL CL2022002606A patent/CL2022002606A1/en unknown
- 2022-11-21 US US17/991,762 patent/US20230118774A1/en active Pending
-
2023
- 2023-10-31 JP JP2023186255A patent/JP2024012435A/en active Pending
-
2024
- 2024-05-23 AU AU2024203448A patent/AU2024203448A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6700348B2 (en) | Sustained drug delivery implant | |
JP7334994B2 (en) | Dendrimer-bioadhesive polymer hydrogel nanoadhesives and uses thereof | |
RU2532333C2 (en) | Intraocular systems of sustained-release drug delivery and method of treating ophthalmic diseases | |
JP2022000441A (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
JP3116489B2 (en) | Sustained release ocular implant preparation | |
HRP20230800T1 (en) | Ocular implant containing a tyrosine kinase inhibitor | |
US20130071349A1 (en) | Biodegradable polymers for lowering intraocular pressure | |
JP2018515529A (en) | Drug delivery from hydrogels | |
JP2005538107A5 (en) | Injectable multimodal polymer depot composition and use thereof | |
JP2007535552A5 (en) | ||
JP2001516258A (en) | Controlled release of the formulation in the anterior chamber | |
JP2014014694A (en) | Sustained-release intraocular implant comprising vasodilator agent | |
JPH10510293A (en) | Controlled release of miotic and mydriatic drugs in the anterior chamber | |
JP2017526655A (en) | Method and biocompatible composition for achieving sustained drug release in the eye | |
WO2017015616A1 (en) | Ocular protein delivery | |
EP3562489A1 (en) | Intraocular drug delivery device and associated methods | |
JPWO2021195163A5 (en) | ||
US20150290170A1 (en) | Ketorolac-containing sustained release drug delivery systems | |
JP2023547607A (en) | Intraocular implants containing active agents | |
US20170105932A1 (en) | Intraocular drug delivery device and associated methods | |
KR102125256B1 (en) | Eye drop carrier, pharmaceutical composition having the same, and method of pharmaceutical composition | |
US20230017509A1 (en) | Injectable drug delivery implant composition and method of use thereof | |
JP2024528257A (en) | Mucoadhesive Ocular Delivery System for the Treatment of Glaucoma - Patent application | |
WO2024081410A1 (en) | Prodrugs, formulations and methods thereof | |
KR20240040105A (en) | Mucoadhesive ocular delivery system for glaucoma treatment |